Phase 1 Study of Cabozantinib in Combination With Topotecan-Cyclophosphamide for Patients With Relapsed Ewing Sarcoma or Osteosarcoma
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Cabozantinib (Primary) ; Cyclophosphamide (Primary) ; Topotecan (Primary) ; Filgrastim; Pegfilgrastim
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Adverse reactions
- 13 Feb 2023 Status changed from active, no longer recruiting to completed.
- 05 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Sep 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2022.